MX2016001095A - Sales de dasatinib en forma cristalina. - Google Patents

Sales de dasatinib en forma cristalina.

Info

Publication number
MX2016001095A
MX2016001095A MX2016001095A MX2016001095A MX2016001095A MX 2016001095 A MX2016001095 A MX 2016001095A MX 2016001095 A MX2016001095 A MX 2016001095A MX 2016001095 A MX2016001095 A MX 2016001095A MX 2016001095 A MX2016001095 A MX 2016001095A
Authority
MX
Mexico
Prior art keywords
dasatinib
substances
crystalline form
salts
relates
Prior art date
Application number
MX2016001095A
Other languages
English (en)
Inventor
Martin Szelagiewicz
Fritz Blatter
Tiziana Chiodo
Andreas Hafner
Tobias Hintermann
Beate Salvador
Bernd Siebenhaar
Marcus Vossen
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2016001095A publication Critical patent/MX2016001095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención principalmente se refiere a sustancias cristalinas moleculares, preferentemente sales de Dasatinib en forma cristalina, que comprenden un compuesto de fórmula 1, preferentemente un catión de un compuesto de fórmula 1. (ver Fórmula) y un segundo compuesto seleccionado del grupo que consiste en ácido glutárico, ácido nicotínico y sacarina, un anión, preferentemente de los anteriores. La invención se refiere en forma adicional a composiciones farmacéuticas que comprenden dicha sustancia. Además, la invención se refiere a procesos para preparar dichas sustancias. La invención se refiere a varios aspectos del uso de dichas sustancias o composiciones farmacéuticas para tratar una enfermedad.
MX2016001095A 2013-07-25 2014-07-22 Sales de dasatinib en forma cristalina. MX2016001095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13178021 2013-07-25
PCT/EP2014/065675 WO2015011120A2 (en) 2013-07-25 2014-07-22 Salts of dasatinib in crystalline form

Publications (1)

Publication Number Publication Date
MX2016001095A true MX2016001095A (es) 2016-04-25

Family

ID=48832838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001095A MX2016001095A (es) 2013-07-25 2014-07-22 Sales de dasatinib en forma cristalina.

Country Status (10)

Country Link
US (1) US9556164B2 (es)
EP (1) EP3024830A2 (es)
JP (1) JP6501773B2 (es)
KR (1) KR20160023879A (es)
CN (1) CN105408329A (es)
AU (1) AU2014295144B2 (es)
CA (1) CA2917183C (es)
MX (1) MX2016001095A (es)
RU (1) RU2662805C2 (es)
WO (1) WO2015011120A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053436B2 (en) 2014-07-08 2018-08-21 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
WO2016180642A1 (en) 2015-05-08 2016-11-17 BASF Agro B.V. A process for the preparation of terpinolene epoxide
WO2016180614A1 (en) 2015-05-08 2016-11-17 Basf Se A process for the preparation of limonene-4-ol
KR20190017924A (ko) 2016-06-15 2019-02-20 바스프 아그로 비.브이. 4치환 알켄의 에폭시화 방법
ES2877169T3 (es) 2016-06-15 2021-11-16 Basf Agro Bv Procedimiento para la epoxidación de un alqueno tetrasustituido
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20070105867A1 (en) 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
KR20100058660A (ko) 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
CN102040596A (zh) * 2009-10-10 2011-05-04 上海希迪制药有限公司 达沙替尼多晶型物及其制备方法
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
AU2012303649A1 (en) 2011-08-30 2014-03-20 Basf Se Co-crystals of cyprodinil and dithianon
CN103059013B (zh) * 2011-10-18 2016-11-23 北京本草天源药物研究院 达沙替尼一水合物的晶型及其制备方法
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
WO2013186726A2 (en) 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
WO2014023682A1 (en) 2012-08-06 2014-02-13 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
AU2013333953B2 (en) 2012-10-19 2017-08-31 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
WO2014097032A1 (en) 2012-12-20 2014-06-26 Basf Se Edge halogenation of graphene materials
WO2014135392A1 (en) 2013-03-07 2014-09-12 Basf Se Co-crystals of pyrimethanil and selected dithiine tetracarboximide

Also Published As

Publication number Publication date
RU2662805C2 (ru) 2018-07-31
EP3024830A2 (en) 2016-06-01
RU2016106125A (ru) 2017-08-30
US20160168143A1 (en) 2016-06-16
WO2015011120A2 (en) 2015-01-29
JP6501773B2 (ja) 2019-04-17
AU2014295144B2 (en) 2017-06-15
CN105408329A (zh) 2016-03-16
AU2014295144A1 (en) 2016-02-11
CA2917183C (en) 2019-01-29
US9556164B2 (en) 2017-01-31
WO2015011120A3 (en) 2015-04-16
KR20160023879A (ko) 2016-03-03
CA2917183A1 (en) 2015-01-29
JP2016527242A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
WO2015011120A3 (en) Salts of dasatinib in crystalline form
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
HK1223917A1 (zh) 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物
MX377202B (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
HK1249504A1 (zh) 用作溴结构域抑制剂的吡啶酮二甲酰胺
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
CY1118514T1 (el) Μεθοδος για την παρασκευη πεμετρεξιδης και αλατος λυσινης αυτης
PH12019500822B1 (en) Crystalline forms of eravacycline
UA117154C2 (uk) Антагоністи s1p3
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
EA201201668A1 (ru) Δ-кристаллическая форма аргининовой соли периндоприла, способ ее получения и содержащие ее фармацевтические композиции
BR112015023222A2 (pt) compostos tetraidroisoquinolin-2-il-(quinazolin-4-il)metanona como inibidores do crescimento de células cancerosas
WO2015002755A3 (en) Compounds for the treatment of malaria